Concepedia

Author

Junning Cao

Fudan University Shanghai Cancer CenterORCID

Also Known As

J. CAO, J. Cao, J.‐N. Cao, JUN-NING CAO, JUNNING CAO, Jinfu Cao, Jiongqing Cao, Jun-Ning Cao, Jun-ning CAO, Jun-ning Cao

233

Publications

1.9K

Citations

24

H-Index

38

Concepts

All Affiliations

Fudan University Shanghai Cancer CenterPeking UniversityPeking University Cancer HospitalSun Yat-sen UniversityChinese Academy of Medical Sciences & Peking Union Medical College
JC

About

Junning Cao is an author at Fudan University Shanghai Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

568

2

Health Sciences

4

4

126

3

Gastroenterology

2

2

31

4

Hepatology

2

2

132

5

Epidemiology

1

1

18

Junning Cao

×

44

Publications

1.6K

Citations

23

H-Index

YearCitations

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Yuqin Song, Jianqiu Wu, Xinchuan Chen,

Clinical Cancer Research

2019

154

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

Seok Jin Kim, Chiun Hsu, Yu-Qin Song,

European Journal of Cancer

2013

121

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

Wenwen Zhang, Shuang Tong, Bingyang Hu,

Journal for ImmunoTherapy of Cancer

2023

109

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

Seok Jin Kim, Hyun Ae Jung, Shih‐Sung Chuang,

Journal of Hematology & Oncology

2013

84

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Rui‐Hua Xu, Jin Li, Yuxian Bai,

Journal of Hematology & Oncology

2017

84

A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

Junning Cao, Jian Zhang, Wei Peng,

Cancer Chemotherapy and Pharmacology

2016

70

Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients

Wenwen Zhang, Bingyang Hu, Jun Han,

Frontiers in Oncology

2021

70

Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma

Xin Liu, Xiaonan Hong, Ya-Jia Gu,

Leukemia & lymphoma/Leukemia and lymphoma

2008

69

Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B‐cell lymphoma patients who are HBsAg‐negative/ HBcAb‐positive: a multicenter retrospective study

Dongmei Ji, Junning Cao, Xiaonan Hong,

European Journal Of Haematology

2010

65

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group

Xiaoyang Li, Zhao Liu, Junning Cao,

Annals of Hematology

2011

52

Page 1